The monoclonal antibody and FVIII mimetic antibody, emicizumab, is one of the few registered non‐replacement therapies used worldwide to treat hemophilia A. Emicizumab is a recombinant, humanized, monoclonal bispecific modified immunoglobulin G4 (IgG4) antibody that bridges activated factor IX and factor X to restore the function of missing activated FVIII in hemophilia A [12]. The gene discussed is F9; the disease is hemophilia A.